请使用支持JavaScript的浏览器!
主营:抗癌化学试剂和激酶抑制剂
banner
当前位置: 首页 > 产品中心 > Angiogenesis > MedKoo/Navitoclaxfeatured/50mg/201970

MedKoo/Navitoclaxfeatured/50mg/201970

  • 产品编号: 201970
  • 美  元  价: $110.00
  • 市  场  价: ¥2200.00
  • 品       牌:
  • 产       地: 美国(厂家直采)
  • 公       司: MedKoo Biosciences, Inc
  • 产品分类:
  • 公司分类: Angiogenesis
MedKoo/Navitoclaxfeatured/50mg/201970
  • MedKoo/Navitoclaxfeatured/50mg/201970
商品介绍

Navitoclax
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#:201970

CAS#:923564-51-6

Description:Navitoclax, also known as ABT-263, is an orally bioavailable, synthetic small-molecule antagonist of a subset of the B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 selectively binds to apoptosis suppressor proteins Bcl-2, Bcl-XL, and Bcl-w and prevents their binding to the apoptotic effectors Bax and Bak proteins, which may trigger apoptosis in tumor cells overexpressing Bcl-2, Bcl-XL, and Bcl-w.

Price and Availability

SizePriceShipping out timeQuantity
50mgUSD 110Same day
100mgUSD 190Same day
200mgUSD 350Same day
500mgUSD 750Same day
1gUSD 1250Same day
2gUSD 2250Same day
5gUSD 4850Same day
10gUSD 76502 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-23.Prices are subject to change without notice.

Navitoclax, purity > 98%, is in stock. The same day shipping after order is received.

Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 201970Name: NavitoclaxCAS#: 923564-51-6Chemical Formula: C47H55ClF3N5O6S3Exact Mass: 973.29551Molecular Weight: 974.61Elemental Analysis:C, 57.92; H, 5.69; Cl, 3.64; F, 5.85; N, 7.19; O, 9.85; S, 9.87

Synonym:ABT 263; ABT-263; ABT263; Navitoclax

IUPAC/Chemical Name:(R)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide

InChi Key:JLYAXFNOILIKPP-KXQOOQHDSA-N

InChi Code:InChI=1S/C47H55ClF3N5O6S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-55-22-24-56(25-23-55)39-14-10-35(11-15-39)45(57)53-65(60,61)41-16-17-43(44(30-41)64(58,59)47(49,50)51)52-38(19-21-54-26-28-62-29-27-54)33-63-40-6-4-3-5-7-40/h3-17,30,38,52H,18-29,31-33H2,1-2H3,(H,53,57)/t38-/m1/s1

SMILES Code:O=C(NS(=O)(C1=CC=C(N[C@H](CCN2CCOCC2)CSC3=CC=CC=C3)C(S(=O)(C(F)(F)F)=O)=C1)=O)C4=CC=C(N5CCN(CC6=C(C7=CC=C(Cl)C=C7)CCC(C)(C)C6)CC5)C=C4

Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:
View CoA: current batch, Lot#A20T03K30

QC Data:
View QC data: current batch, Lot#A20T03K30

Safety Data Sheet (SDS):
View Safety Data Sheet (SDS)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Additional Information

Bcl-2, Bcl-XL, and Bcl-w are frequently overexpressed in a wide variety of cancers, including those of the lymphatic system, breast, lung, prostate, and colon, and have been linked to tumor drug resistance.

References

1: Kaefer A, Yang J, Noertersheuser P, Mensing S,Humerickhouse R, Awni W, Xiong H. Mechanism-based pharmacokinetic/pharmacodynamicmeta-analysis of navitoclax (ABT-263) induced thrombocytopenia. CancerChemother Pharmacol. 2014 Sep;74(3):593-602. doi:10.1007/s00280-014-2530-9. Epub 2014 Jul 23. PubMed PMID: 25053389.

2: Yang J, Pradhan RS, Rosen LS, Graham AM, Holen KD, Xiong H. Effect ofrifampin on the pharmacokinetics, safety and tolerability of navitoclax(ABT-263), a dual inhibitor of Bcl-2 and Bcl-X(L) , in patients withcancer. J Clin Pharm Ther. 2014 Jul 22. doi: 10.1111/jcpt.12193. [Epubahead of print] PubMed PMID: 25047139.

3: Wei X, Zhou P, Lin X, Lin Y, Wu S, Diao P, Xie H, Xie K, Tang P.MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostatecancer cells by induction of NOXA. Tumour Biol. 2014 Jul 17. [Epub aheadof print] PubMed PMID: 25027405.

4: Suryani S, Carol H, Chonghaile TN, Frismantas V, Sarmah C, High L,Bornhauser B, Cowley MJ, Szymanska B, Evans K, Boehm I, Tonna E, JonesL, Manesh DM, Kurmasheva RT, Billups C, Kaplan W, Letai A, Bourquin JP,Houghton PJ, Smith MA, Lock RB. Cell and Molecular Determinants of InVivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric AcuteLymphoblastic Leukemia Xenografts. Clin Cancer Res. 2014 Sep1;20(17):4520-31. doi: 10.1158/1078-0432.CCR-14-0259. Epub 2014 Jul 10.PubMed PMID: 25013123; PubMed Central PMCID: PMC4154988.

5: Polier G, Giaisi M, Köhler R, Müller WW, Lutz C, Buss EC, Krammer PH,Li-Weber M. Targeting CDK9 by wogonin and related natural flavonespotentiates the anti-cancer efficacy of the Bcl-2 family inhibitorABT-263. Int J Cancer. 2014 Jun 4. doi: 10.1002/ijc.29009. [Epub aheadof print] PubMed PMID: 24895203.

6: Vlahovic G, Karantza V, Wang D, Cosgrove D, Rudersdorf N, Yang J,Xiong H, Busman T, Mabry M. A phase I safety and pharmacokinetic studyof ABT-263 in combination with carboplatin/paclitaxel in the treatmentof patients with solid tumors. Invest New Drugs. 2014 Oct;32(5):976-84.doi: 10.1007/s10637-014-0116-3. Epub 2014 Jun 5. PubMed PMID: 24894650.

7: Wang X, Gu Z, Li G, Zhang S, Cao Z, Yang Z, Liu G. Norcantharidinenhances ABT-263-mediated anticancer activity in neuroblastoma cells byupregulation of Noxa. Oncol Rep. 2014 Aug;32(2):716-22. doi:10.3892/or.2014.3228. Epub 2014 May 30. PubMed PMID: 24891300.

8: Wang B, Ni Z, Dai X, Qin L, Li X, Xu L, Lian J, He F. The Bcl-2/xLinhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein inhepatocellular carcinoma cells. Mol Cancer. 2014 Apr 30;13:98. doi:10.1186/1476-4598-13-98. PubMed PMID: 24779770; PubMed Central PMCID:PMC4021276.

9: Li J, Chen Y, Wan J, Liu X, Yu C, Li W. ABT-263 enhances sorafenib-inducedapoptosis associated with Akt activity and the expression of Bax andp21((CIP1/WAF1)) in human cancer cells. Br J Pharmacol. 2014Jul;171(13):3182-95. doi: 10.1111/bph.12659. PubMed PMID: 24571452;PubMed Central PMCID: PMC4080973.

10: Choo EF, Boggs J, Zhu C, Lubach JW, Catron ND, Jenkins G, Souers AJ,Voorman R. The role of lymphatic transport on the systemicbioavailability of the Bcl-2 protein family inhibitors navitoclax(ABT-263) and ABT-199. Drug Metab Dispos. 2014 Feb;42(2):207-12. doi:10.1124/dmd.113.055053. Epub 2013 Nov 8. PubMed PMID: 24212376.

品牌介绍


MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务。

MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务和分子有竞争力的价格。MedKoo是您可靠的合作伙伴采购药物发现和药物分子。



MedKoo,由化学家和药学家陈清奇博士。北卡罗莱纳州的研究三角区(Research Triangle Park, 简称 RTP ),是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司,该公司的业务范围主要是为全球所有从事抗癌药物研究和开发的制药公司,高校,研究院所,政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。
中文名MedKoo中    文美帝药库医药科技公司创立于2008年总部位于美国东海岸

蚂蚁淘(ebiomall)作为一家生命科学领域的垂直电商平台,公司专注生物医学科研用品的全球导购和品牌推广,为海内外厂方与代理经销商搭建跨境贸易系统和交流平台。产品齐全,200+分类,1000+品牌,500万+产品信息。100%正品,专业售后,到货快,在线下单, 简单轻松,节省科学家宝贵的科研时间。为您竭诚服务!

【订购】蚂蚁淘生物科技  联系方式:4000-520-616

更多产品,更多优惠!请联系我们!

苏州蚂蚁淘生物科技有限公司

免费热线:4000-520-616

官网:https://www.ebiomall.cn/


自营商城图标
厂家直采
全球直采模式 正品优价
正品保障图标
正品保障
厂家直发 有线跟踪
解放采购图标
正规清关
CIF100%正规报关,提供发票
及时交付图标
及时交付
限时必达 不达必赔
在线客服
客服电话

4000-520-616

0512-67156496